Journalartikel

Human papillomavirus and squamous cell cancer of the head and neck region. Prognostic, therapeutic and prophylactic implications


AutorenlisteReuschenbach, M.; Wagner, S.; Wuerdemann, N.; Sharma, S. J.; Prigge, E. -S.; Sauer, M.; Wittig, A.; Wittekindt, C.; Doeberitz, M. von Knebel; Klussmann, J. P.

Jahr der Veröffentlichung2016

Seiten450-45+

ZeitschriftHNO

Bandnummer64

Heftnummer7

ISSN0017-6192

eISSN1433-0458

DOI Linkhttps://doi.org/10.1007/s00106-016-0123-0

VerlagSpringer


Abstract
Human papilloma viruses (HPV) are responsible for approximately half of all oropharyngeal squamous cell carcinomas (OPSCC) and incidence rates of HPV-associated OPSCC continue to increase substantially. The defined viral carcinogenesis permits development of specific diagnostic, therapeutic, and prophylactic approaches. Laboratory identification of HPV-associated OPSCC may be achieved by p16(INK4a) immunohistochemistry combined with HPV DNA detection by polymerase chain reaction (PCR) using tumor tissue. Patients with HPV-associated OPSCC have a relatively good prognosis; therefore, the HPV status plays an important role in patient guidance. Due to the relatively favorable prognosis, ongoing studies are evaluating whether less rigorous therapy for HPV-positive patients results in equally good cure rates. The criteria for patient selection are, however, still uncertain. Particularly markers for detection of HPV-positive patients with a high risk of treatment failure are lacking. Besides tumor stage and comorbidities, distinct genomic, epigenetic, and immunologic alterations are prognostically relevant for HPV-associated OPSCC, and might be of predictive value. Furthermore, the characteristic molecular alterations suggest the possibility of novel vigilant and specific therapy approaches. These may be inhibitors of the phosphatidylinositol 3aEurokinase (PI3K) pathway, which is frequently activated in HPV-associated OPSCC, and immunotherapeutic methods, e. g., therapeutic vaccination. Although prophylactic HPV vaccinations may also prevent development of HPV-associated OPSCC, foreseeable effects on OPSCC incidence will be low, given the low vaccination rates in Germany. This highlights the fact that interdisciplinary research networks should enhance the necessary activities related to HPV-associated OPSCC.



Zitierstile

Harvard-ZitierstilReuschenbach, M., Wagner, S., Wuerdemann, N., Sharma, S., Prigge, E., Sauer, M., et al. (2016) Human papillomavirus and squamous cell cancer of the head and neck region. Prognostic, therapeutic and prophylactic implications, HNO, 64(7), pp. 450-45+. https://doi.org/10.1007/s00106-016-0123-0

APA-ZitierstilReuschenbach, M., Wagner, S., Wuerdemann, N., Sharma, S., Prigge, E., Sauer, M., Wittig, A., Wittekindt, C., Doeberitz, M., & Klussmann, J. (2016). Human papillomavirus and squamous cell cancer of the head and neck region. Prognostic, therapeutic and prophylactic implications. HNO. 64(7), 450-45+. https://doi.org/10.1007/s00106-016-0123-0



Schlagwörter


Active immunotherapyHPV-ASSOCIATED HEADOROPHARYNGEAL CANCERoropharyngeal carcinomaP16(INK4A)PHOSPHATIDYLINOSITOL 3-KINASEPOSITIVE HEADROBOTIC SURGERYTONSILLAR CARCINOMAS

Zuletzt aktualisiert 2025-02-04 um 01:46